Eprosartan

Drug Profile

Eprosartan

Alternative Names: eprosartan mesylate; Navixen; SKB 108566; SKF 108566; Teveten; Teveten SB; Tevetens; Tevetenz

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Acrylates; Antihypertensives; Heart failure therapies; Imidazoles; Small molecules; Thiophenes
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Essential hypertension
  • Discontinued Heart failure; Renal failure

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 27 Dec 2011 First generic equivalent approved and launched in USA for Essential hypertension
  • 13 Dec 2006 Kos Pharmaceuticals has been acquired by Abbott Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top